Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Cisplatin + Gemcitabine + Toripalimab
Indication/Tumor Type nasopharynx carcinoma
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown nasopharynx carcinoma not applicable Cisplatin + Gemcitabine + Toripalimab Phase II Actionable In a Phase II trial, Toripalimab (JS001) in combination with Gemzar (gemcitabine) and Platinol (cisplatin) resulted in an objective response rate of 75.0% (9/12) and a disease control rate of 83.3% (10/12) in patients with metastatic nasopharyngeal carcinoma, with a median duration of response of 7.7 months (J Clin Oncol 38: 2020 (suppl; abstr e15083); NCT02915432). detail...
PubMed Id Reference Title Details
Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors. Full reference...